Clinical Trials Logo

Advanced Lymphoma clinical trials

View clinical trials related to Advanced Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05833893 Recruiting - Advanced Lymphoma Clinical Trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

Patients with newly diagnosed, pathologically confirmed NK/T-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.

NCT ID: NCT05279300 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Start date: March 28, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 in patients with advanced hematological and solid tumors.

NCT ID: NCT05053971 Recruiting - Clinical trials for Advanced Malignant Solid Neoplasm

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas

Start date: November 16, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety, side effects, and best dose of entinostat and ZEN003694 in treating patients with solid tumors or lymphoma that has spread to other places in the body (advanced) or does not respond to treatment (refractory). Entinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is in a class of drugs called histone deacetylase (HDAC) inhibitor. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). ZEN003694 may prevent the growth of tumor cells that produce high levels of BET protein. This trial aims to test the safety of combination therapy with entinostat and ZEN003694 in treating patients with advanced or refractory solid tumors or lymphoma.

NCT ID: NCT04999384 Recruiting - Clinical trials for Advanced Solid Tumor

First in Human, Dose Escalation Study of AN4005

Start date: September 27, 2021
Phase: Phase 1
Study type: Interventional

Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional "3 + 3 design" will be utilized for dose finding with dose escalation and/or de-escalation as appropriate.

NCT ID: NCT04470947 Recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

EXALT-2
Start date: June 10, 2020
Phase:
Study type: Observational [Patient Registry]

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice